Skip to main

340B Podcast Series, Episode 3: A Deep Dive Into the Growth Drivers Behind the Recently Released 340B Program Purchase Numbers from HRSA with Clay Willis

340B

In this episode, Clay Willis, Partner of Advisory Services at IntegriChain, unpacks the real forces behind 340B's continued growth, such as expanding patient definitions, telehealth referral models, contract pharmacy state access laws, and more. Also discussed are key market pressures on the horizon including IRA and Medicare pricing impacts and Part B reimbursement changes.

Listeners will come away with a better picture of what's fueling 340B program expansion, where scrutiny is increasing, and what to watch for as HRSA prepares further updates.

About this Episode

In July 2026, HRSA released its 340B purchase data for 2025, showing covered entity purchases passed $100 billion for the first time. Clay breaks down how much 340B grew, why HRSA’s explanation of price increases and new therapies doesn’t tell the whole story, and the utilization-based drivers behind the numbers, from in-house purchasing at 340B hospitals to higher capture rates and contract pharmacy expansion. He also looks at what could slow growth and why the early timing of HRSA’s release stands out.

Episode Highlights

  • 340B covered entity purchases passed $100 billion in 2025, about 24% growth over 2024. Valued at list price, those purchases would top $180 billion.
  • Disproportionate share hospitals account for over 80% of 340B purchases, with oncology, immunology, and obesity as the leading therapeutic areas.
  • Clay points to three main growth drivers: a shift in site of care to in-house at 340B hospitals, higher 340B capture rates, and continued contract pharmacy expansion.
  • 340B contract pharmacy state access laws now cover more than 20 states, reopening access that manufacturer contract pharmacy policies had restricted.

Listen Here

FAQs

How much has the 340B program grown?

Covered entities purchased more than $100 billion in drugs at 340B discounted prices in 2025, up about 24% from 2024. Valued at list price, that total would be more than $180 billion.

What did HRSA’s latest 340B data show?

HRSA’s 340B data for calendar year 2025 showed covered entity purchases passing $100 billion for the first time. HRSA released the numbers in mid-July 2026, several months earlier than its usual Q4 timing.

Which 340B covered entities drive the most purchases?

340B hospitals, specifically disproportionate share hospitals, account for more than 80% of covered entity purchases and remain the main source of program growth.

What are 340B contract pharmacy state access laws?

These state laws limit manufacturers’ ability to restrict 340B pricing at contract pharmacies. More than 20 states have passed them, reopening access that many manufacturer contract pharmacy policies had cut off.

Catch Up on the 340B Podcast Series

New to the series? Episode 2 covers the 340B Rebate Model and what HRSA’s pilot program means for manufacturers with MFP-selected drugs.

Listen to Episode 2: The Rebate Model

Talk to a 340B Expert

Contact Us